IQVIA (IQV) Expected to Announce Earnings on Tuesday

IQVIA (NYSE:IQV) is expected to release its Q3 2025 results before the market opens on Tuesday, October 28th. Analysts expect IQVIA to post earnings of $2.96 per share and revenue of $4.0738 billion for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, October 28, 2025 at 9:00 AM ET.

IQVIA Stock Performance

IQV opened at $220.64 on Monday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The company’s fifty day moving average price is $194.47 and its two-hundred day moving average price is $171.56. IQVIA has a 1-year low of $134.65 and a 1-year high of $225.91. The company has a market cap of $37.51 billion, a price-to-earnings ratio of 31.93, a PEG ratio of 2.42 and a beta of 1.32.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on IQV. Jefferies Financial Group upgraded shares of IQVIA from a “hold” rating to a “buy” rating and upped their target price for the stock from $195.00 to $225.00 in a research note on Tuesday, September 9th. William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research note on Saturday. Mizuho upped their target price on shares of IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Finally, Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $234.57.

Hedge Funds Weigh In On IQVIA

Institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC lifted its holdings in IQVIA by 130.2% during the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after purchasing an additional 879,701 shares during the last quarter. Worldquant Millennium Advisors LLC lifted its holdings in IQVIA by 90.8% during the second quarter. Worldquant Millennium Advisors LLC now owns 429,802 shares of the medical research company’s stock valued at $67,732,000 after purchasing an additional 204,571 shares during the last quarter. Glenview Capital Management LLC purchased a new stake in IQVIA during the second quarter valued at about $15,759,000. Orbis Allan Gray Ltd purchased a new stake in IQVIA during the second quarter valued at about $8,225,000. Finally, Ieq Capital LLC lifted its holdings in IQVIA by 118.0% during the second quarter. Ieq Capital LLC now owns 90,824 shares of the medical research company’s stock valued at $14,313,000 after purchasing an additional 49,160 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.